Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07296120 · ClinicalTrials.gov registry record · Phase 4
RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients
A Phase 4 study, sponsored by The Cooper Health System.
- Not yet
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT07296120 is a Phase 4 study that has not yet begun recruiting, run by The Cooper Health System. The registered enrollment target is 30 participants.
The verdict
NCT07296120, a Phase 4 study, has not yet begun recruiting, sponsored by The Cooper Health System.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus. The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, defined as at least a four-fold increase in RSV neutralizing antibody levels four weeks after vaccination.
Interventions
- BIOLOGICAL Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07296120
The ClinicalTrials.gov registry entry for NCT07296120 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cooper Health System, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) is the first listed.
NCT07296120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07296120 about?
NCT07296120 is a clinical study titled "RSV Vaccine Response in Stem Cell and CAR-T Therapy Recipients". This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important compon...
What is the current status of trial NCT07296120?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2026-01-01. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07296120?
The interventions under investigation include: Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07296120?
This trial is sponsored by The Cooper Health System, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.